HCMV Virus Infectivity via LRP1 Inhibition and Cholesterol Modulation

The patent applies preliminary action by adding lipids to the culture medium before virus infection occurs, during the cell growth phase. This timing allows the lipids to be incorporated into the cell membrane structure in advance, stabilizing it before the virus production phase begins, thereby avoiding the inhibitory effect of lipid addition during active virus replication

The patent changes the parameter of lipid concentration in the culture medium by optimizing the amount and type of lipids added during cell growth. By carefully controlling lipid parameters (concentration, timing, composition), the method achieves cell membrane stabilization without triggering the inhibitory effect on virus production that occurs when lipids are added during infection

The patent applies preliminary action by providing exogenous lipids to cells before virus infection, ensuring that cell membranes are pre-loaded with sufficient lipid content. This preliminary lipid supplementation allows the cells to maintain membrane integrity and function during virus production without relying on de novo fatty acid synthesis, which would otherwise be required for virus infectivity

The patent uses exogenous lipids as an intermediary substance that mediates between cell growth requirements and virus infectivity needs. The added lipids serve as a substitute for de novo fatty acid synthesis, providing the necessary lipid components for virus particle assembly and infectivity without requiring the cell to actively synthesize fatty acids during infection